Carregant...
Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months
BACKGROUND: Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox(®) was evaluated in a target animal safety study: Groups of 4 dogs per sex ea...
Guardat en:
| Publicat a: | BMC Vet Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8173827/ https://ncbi.nlm.nih.gov/pubmed/34082759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12917-021-02910-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|